Back to results
US 8,796,269 B2Granted
Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
AssigneeNeRRe Therapeutics Limited
InventorsAndrew Simon Craig, Salima Zarah Ismail, Ronnie Maxwell Lawrence
Life of this patent
Estimating the term…
Abstract
The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.
Claims9
A compound of formula (I):
- in a crystalline anhydrate form and having an X-ray powder diffraction pattern comprising 2 theta angle peaks at 7.9°±0.1, 9.8°±0.1, and 10.8°±0.1 which correspond respectively to d-spacing at 11.1, 9.0, and 8.2 Å.
A compound of formula (I):
- in crystalline anhydrate form, having the same 13C solid state nuclear magnetic resonance spectrum as in FIG. 3.
Dependencies are inferred from the claim text.